Literature DB >> 20492324

A fresh look at NASH pathogenesis. Part 1: the metabolic movers.

Claire Z Larter1, Shiv Chitturi, Déborah Heydet, Geoffrey C Farrell.   

Abstract

The strong relationship between over-nutrition, central obesity, insulin resistance/metabolic syndrome and non-alcoholic fatty liver disease (NAFLD) suggest pathogenic interactions, but key questions remain. NAFLD starts with over-nutrition, imbalance between energy input and output for which the roles of genetic predisposition and environmental factors (diet, physical activity) are being redefined. Regulation of energy balance operates at both central nervous system and peripheral sites, including adipose and liver. For example, the endocannabinoid system could potentially be modulated to provide effective pharmacotherapy of NAFLD. The more profound the metabolic abnormalities complicating over-nutrition (glucose intolerance, hypoadiponectinemia, metabolic syndrome), the more likely is NAFLD to take on its progressive guise of non-alcoholic steatohepatitis (NASH). Interactions between steatosis and insulin resistance, visceral adipose expansion and subcutaneous adipose failure (with insulin resistance, inflammation and hypoadiponectinemia) trigger amplifying mechanisms for liver disease. Thus, transition from simple steatosis to NASH could be explained by unmitigated hepatic lipid partitioning with failure of local adaptive mechanisms leading to lipotoxicity. In part one of this review, we discuss newer concepts of appetite and metabolic regulation, bodily lipid distribution, hepatic lipid turnover, insulin resistance and adipose failure affecting adiponectin secretion. We review evidence that NASH only occurs when over-nutrition is complicated by insulin resistance and a highly disordered metabolic milieu, the same 'metabolic movers' that promote type 2 diabetes and atheromatous cardiovascular disease. The net effect is accumulation of lipid molecules in the liver. Which lipids and how they cause injury, inflammation and fibrosis will be discussed in part two.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492324     DOI: 10.1111/j.1440-1746.2010.06253.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  51 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Maria Stepanova; Nila Rafiq; Hala Makhlouf; Ritambhara Agrawal; Ishmeet Kaur; Zahra Younoszai; Arthur McCullough; Zachary Goodman; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2013-06-18       Impact factor: 3.199

3.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

Review 4.  Intermittent Fasting: Is the Wait Worth the Weight?

Authors:  Mary-Catherine Stockman; Dylan Thomas; Jacquelyn Burke; Caroline M Apovian
Journal:  Curr Obes Rep       Date:  2018-06

Review 5.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

6.  Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease.

Authors:  Susanne Bonekamp; An Tang; Arian Mashhood; Tanya Wolfson; Christopher Changchien; Michael S Middleton; Lisa Clark; Anthony Gamst; Rohit Loomba; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2014-06       Impact factor: 4.813

Review 7.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

8.  Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice.

Authors:  Christopher M Depner; Moises Torres-Gonzalez; Sasmita Tripathy; Ginger Milne; Donald B Jump
Journal:  J Nutr       Date:  2012-06-27       Impact factor: 4.798

Review 9.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

Review 10.  Fatty acid-regulated transcription factors in the liver.

Authors:  Donald B Jump; Sasmita Tripathy; Christopher M Depner
Journal:  Annu Rev Nutr       Date:  2013-03-22       Impact factor: 11.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.